Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Dr María Natalia Gandur Quiroga at ASCO GU 2026 gives a comprehensive update exploring the evolving landscape of advanced prostate cancer, with a global perspective that emphasises both scientific progress and real-world accessibility.
In this discussion, she breaks down three defining themes shaping modern care: smarter treatment intensification, optimal sequencing of radioligand therapies, and the growing role of biomarker-driven decision-making.
| Comparison of docetaxel triplet therapy with androgen receptor pathway inhibitor (ARPI) doublet in US veterans with metastatic hormone sensitive prostate cancer (mHSPC) | |
| Hormone therapy use and duration with post-operative radiotherapy for recurrent prostate cancer: An individual patient data meta-analysis | |
| Impact of age, number of cycles of chemotherapy and presence of visceral metastases on PSA response in patients on triplet therapy (ADT + darolutamide + docetaxel) for mHSPC: UK real world data from the RECOMMEND study | |
| Saruparib + androgen receptor pathway inhibitor (ARPI) + androgen deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase 1/2 PETRANHA trial | |
| Treatment utilization among patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in real-world US settings: A prostate cancer disease observation (PRECISION) data platform analysis | |
| Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer | |
| ProTACT: A First-in-Human, Phase 1 Study Evaluating the Safety, Tolerability, and Anti-Tumor Activity of 225Ac-FL-020, an Anti-PSMA Radioconjugate in Patients with mCRPC | |
| Gaps in BRCA mutation testing among mCRPC patients: Insights from US cancer practices (2018–2024) | |
| Circulating tumor DNA (ctDNA) dynamics in bone-dominant metastatic castration resistant prostate cancer (mCRPC) treated with radium-223 with or without olaparib: Biomarker analyses from the multicenter, randomized, phase 2, investigator-initiated COMRADE trial | |
| Development and Validation of CHAI-Powered Prognostic and Predictive Biomarkers in mHSPC Using ENZAMET and CHAARTED Prospective Randomized Phase 3 Trials |
